Increasing unusual call option volume: VIRT AUR AGEN ITB APTV KOPN LPSN
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Jefferies Downgrades Agenus Inc. (AGEN) to Hold
July 19, 2024 8:55 AM EDTJefferies analyst Biren Amin downgraded Agenus Inc. (NASDAQ: AGEN) from Buy to Hold with a price target of $7.00 (from $3.00).
The analyst comments "The FDA advised against the BLA submission of BOT+BAL in MSS-CRC for accelerated approval, citing ORR may not... More
H.C. Wainwright Downgrades Agenus Inc. (AGEN) to Neutral
July 18, 2024 12:34 PM EDTH.C. Wainwright analyst Emily Bodnar downgraded Agenus Inc. (NASDAQ: AGEN) from Buy to Neutral, PT $9
The analyst comments "FDA advises against accelerated approval pathway; interim Phase 2 data give rise to questions. This morning, Agenus announced that it has completed the end of Phase 2 meeting with the FDA regarding bot/bal next steps for treatment of relapsed/refractory microsatellite stable colorectal cancer (MSS-CRC) and also announced interim data from the Phase 2 bot/bal study in MSS-CRC. The FDA has advised against the accelerated... More
